Loading
itRECIST adapts the scan-measuring rules for trials in which the immunotherapy is injected straight into a tumour, so that injected and uninjected tumours are tracked separately.
Goldmacher and colleagues (Journal of Clinical Oncology 2020) published itRECIST, response criteria for intratumoural immunotherapy in solid tumours. The CDISC oncology response codelist holds it as itRECIST Goldmacher 2020. No abstract was available to read, so this record states only what the title and the codelist say: it is a RECIST-based set of criteria for treatments injected into tumours.
Showing the technology this term belongs to: Intratumoural gene electrotransfer (IL-12 plasmid).
Shares iRECIST (response criteria for immunotherapy trials), RECIST.
Shares iRECIST (response criteria for immunotherapy trials), RECIST.
Shares iRECIST (response criteria for immunotherapy trials), RECIST.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/